

Yufan Ying

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6488284/publications.pdf>

Version: 2024-02-01

22
papers

735
citations

687363

13
h-index

677142

22
g-index

22
all docs

22
docs citations

22
times ranked

768
citing authors

#	ARTICLE	IF	CITATIONS
1	SMAD3 and FTO are involved in miR-5581-3p-mediated inhibition of cell migration and proliferation in bladder cancer. <i>Cell Death Discovery</i> , 2022, 8, 199.	4.7	10
2	Prognostic Value of Tumor-Associated Macrophages in Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 657318.	2.8	28
3	Upregulation of ARNTL2 is associated with poor survival and immune infiltration in clear cell renal cell carcinoma. <i>Cancer Cell International</i> , 2021, 21, 341.	4.1	11
4	Comprehensive Analysis of Ferroptosis Regulators With Regard to PD-L1 and Immune Infiltration in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 676142.	3.7	29
5	EGR2-mediated regulation of m6A reader IGF2BP proteins drive RCC tumorigenesis and metastasis via enhancing S1PR3 mRNA stabilization. <i>Cell Death and Disease</i> , 2021, 12, 750.	6.3	37
6	miR-665 inhibits epithelial-to-mesenchymal transition in bladder cancer via the SMAD3/SNAIL axis. <i>Cell Cycle</i> , 2021, 20, 1242-1252.	2.6	16
7	MicroRNA-501a-3p inhibits the proliferation of kidney cancer cells by targeting WTAP. <i>Cancer Medicine</i> , 2021, 10, 7222-7232.	2.8	17
8	The Regulatory Role of RNA Metabolism Regulator TDP-43 in Human Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 755096.	2.8	9
9	Diverse Roles and Therapeutic Potentials of Circular RNAs in Urological Cancers. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 761698.	3.5	1
10	circKDM4C enhances bladder cancer invasion and metastasis through miR-200bc-3p/ZEB1 axis. <i>Cell Death Discovery</i> , 2021, 7, 365.	4.7	15
11	YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer. <i>Molecular Cancer</i> , 2020, 19, 152.	19.2	159
12	Roles of N ⁶ -methyladenosine (m ⁶ A) RNA modifications in urological cancers. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 10302-10310.	3.6	10
13	METTL3/YTHDF2 m ⁶ A axis promotes tumorigenesis by degrading SETD7 and KLF4 mRNAs in bladder cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 4092-4104.	3.6	100
14	CCND1, NOP14 and DNMT3B are involved in miR-502a-5p-mediated inhibition of cell migration and proliferation in bladder cancer. <i>Cell Proliferation</i> , 2020, 53, e12751.	5.3	45
15	Lower circulating adiponectin is associated with higher risk of renal cell carcinoma: A meta-analysis. <i>International Journal of Biological Markers</i> , 2020, 35, 57-64.	1.8	8
16	Dual regulatory role of CCNA2 in modulating CDK6 and MET-mediated cell cycle pathway and EMT progression is blocked by miR-381a-3p in bladder cancer. <i>FASEB Journal</i> , 2019, 33, 1374-1388.	0.5	60
17	Dysregulation of ncRNAs located at the DLK1-DIO3 imprinted domain: involvement in urological cancers. <i>Cancer Management and Research</i> , 2019, Volume 11, 777-787.	1.9	20
18	MIR-300 in the imprinted DLK1-DIO3 domain suppresses the migration of bladder cancer by regulating the SP1/MMP9 pathway. <i>Cell Cycle</i> , 2018, 17, 2790-2801.	2.6	26

#	ARTICLE	IF	CITATIONS
19	Secondhand smoking increases bladder cancer risk in nonsmoking population: a meta-analysis. <i>Cancer Management and Research</i> , 2018, Volume 10, 3781-3791.	1.9	25
20	The dual role of N6-methyladenosine modification of RNAs is involved in human cancers. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 4630-4639.	3.6	72
21	Pioglitazone use in patients with diabetes and risk of bladder cancer: a systematic review and meta-analysis. <i>Cancer Management and Research</i> , 2018, Volume 10, 1627-1638.	1.9	24
22	CRISPR-ON-Mediated KLF4 overexpression inhibits the proliferation, migration and invasion of urothelial bladder cancer <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2017, 8, 102078-102087.	1.8	13